Navigation Links
Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Date:5/21/2009

PRINCETON, N.J., May 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has entered into a research agreement with Cephalon, Inc. (Nasdaq: CEPH). The research agreement provides for the exploration of the application of Celator's proprietary technology to an ongoing drug development and life-cycle management program at Cephalon.

"This agreement provides an opportunity to leverage the technology and expertise at Celator beyond our own pipeline," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "It is exciting to advance our capabilities with such a high caliber partner as well as through progress in our clinical programs. We believe our technology has the potential to improve clinical outcomes with a wide variety of cancer products and we continue to seek additional partners."

"Celator has developed unique capabilities in liposomal and nano-particle encapsulation," said Jeffry Vaught, Ph.D., chief scientific officer at Cephalon. "Exploring their utility for Cephalon pipeline compounds is entirely consistent with our commitment to use drug delivery technology to optimize treatment and improve patient care."

Terms and conditions of the research agreement are confidential.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. Cephalon currently markets five products for treatment of patients with cancer. In addition, the company currently has six compounds for oncology targets in development. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.


'/>"/>
SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
2. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
3. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
8. Sagent Pharmaceuticals Announces Extension of Series A Financing
9. NSD Bio Group, LLC Selected By U.S. - China Economic & Security Review Commission for Analysis of Chinas Pharma Supply Chain on U.S. Pharmaceuticals
10. Aragon Pharmaceuticals Announces $8 Million Series A Financing
11. Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology: